What is Oxstem?
Oxstem is a biopharmaceutical company focused on discovering small molecules designed to activate or reprogram endogenous stem and progenitor cells. The company targets diseases with substantial unmet clinical needs, pursuing six distinct research programs. These initiatives aim to create first-in-class therapeutics for a range of conditions including haematological malignancies, neurodegenerative diseases, retinal diseases, cardiovascular diseases, inflammation, and diabetes. The company's approach leverages the body's own regenerative capabilities to address complex health challenges.
How much funding has Oxstem raised?
Oxstem has raised a total of $24.3M across 1 funding round:
Private Equity
$24.3M
Private Equity (2016): $24.3M, investors not publicly disclosed
What's next for Oxstem?
The recent major strategic investment signals a pivotal moment for Oxstem, likely enabling the acceleration of its research programs and the advancement of its therapeutic candidates through preclinical and clinical development stages. This enterprise-level funding provides the necessary resources to scale operations, expand its scientific team, and potentially forge strategic partnerships to bring its innovative treatments to market. Oxstem's focus on endogenous cell reprogramming positions it at the forefront of regenerative medicine, with significant potential for future growth and impact.
See full Oxstem company page
